Adicet Bio, Inc. (ACET) — DEF 14A Filings
All DEF 14A filings from Adicet Bio, Inc.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Adicet Bio Seeks Reverse Split to Avoid Nasdaq Delisting
— Nov 17, 2025 Risk: high
Adicet Bio, Inc. (ACET) is proposing a reverse stock split at a ratio of one-for-five to one-for-thirty to address its non-compliance with Nasdaq's minimum bid -
Adicet Bio Reveals Executive Compensation Details
— Apr 29, 2025 Risk: low
Adicet Bio, Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation and equity awards. For the fiscal year ending December 31, 2024, the compan -
Adicet Bio, Inc. Files DEF 14A with Executive Compensation Details
— Apr 23, 2024 Risk: low
Adicet Bio, Inc. (ACET) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Adicet Bio, Inc. filed a DEF 14A form on April 23, 2024. The filing co
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX